Across TCGA pan-cancer cohorts, ECT2L mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ECT2L data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ECT2L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ECT2L expression acts as an unfavorable survival marker.

LUAD are the cancer types where ECT2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.365	0.866	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: ECT2L tumor-vs-normal RNA expression · all ECT2L data types